Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05869643 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
A Phase 2 study of HIV-1-infection, sponsored by ST Pharm Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 13
- Study locations
NCT05869643 is a Phase 2 study of HIV-1-infection that is actively recruiting participants, run by ST Pharm Co.. The registered enrollment target is 36 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (90% lower). The trial reports 13 study locations across 7 states.
The verdict
NCT05869643, a Phase 2 study of HIV-1-infection, is actively recruiting participants, sponsored by ST Pharm Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low-dose STP0404 (Pirmitegravir)
- DRUG Medium-dose STP0404 (Pirmitegravir)
- DRUG High-dose STP0404 (Pirmitegravir)
Study Locations (13)
Florida
- Midway Immunology and Research Center - Ft. Pierce
- Schiff Center for Liver Diseases/University of Miami - Miami
- Orlando Immunology Center - Orlando
- USF Health South Tampa Center for Advanced Healthcare - Tampa
California
- Kaiser Permenente Los Angeles Medical Center - Los Angeles
- Ruane Clinical Research, Inc. - Los Angeles
New Jersey
- Saint Michael's Medical Center - Newark
- South Jersey Infectious Disease - Somers Point
Texas
- St Hope Foundation, Inc - Bellaire
- North Texas Infectious Diseases Consultants, P.A. - Dallas
Michigan
- Be Well Medical Center - Berkley
New York
- North Shore University Hospital - Manhasset
North Carolina
- Atrium Health Wake Forest Baptist Medical Center - PPDS - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05869643
The ClinicalTrials.gov registry entry for NCT05869643 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (90% lower). The listed sponsor is ST Pharm Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05869643 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05869643 about?
NCT05869643 is a clinical study titled "A Clinical Trial of STP0404 in Adults With HIV-1 Infection". The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
What is the current status of trial NCT05869643?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-05-23. Estimated completion is 2026-04-30.
What conditions does trial NCT05869643 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05869643?
The interventions under investigation include: Placebo (DRUG), Low-dose STP0404 (Pirmitegravir) (DRUG), Medium-dose STP0404 (Pirmitegravir) (DRUG), High-dose STP0404 (Pirmitegravir) (DRUG).
Who is sponsoring clinical trial NCT05869643?
This trial is sponsored by ST Pharm Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05869643 being conducted?
This trial has 13 study locations across California, Florida, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
PrEPsmart 2-1-1 Pilot
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
RECRUITING · Phase 2
-
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.